The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 50 | — | 20.1x | Near average | |
Growth | 21 | -0.3% | 5.6% | Below average | |
Quality | 32 | -79.7% | 7.6% | Below average | |
Safety | 31 | 0.1x | 0.4x | Below average | |
Capital Return | 12 | — | 2.19% | Below average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Myriad Genetics, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Myriad Genetics, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
Analyst reviews for Myriad Genetics (MYGN) showed a state of complete stability in price targets over the past 7 and 30-day periods, with the average price target stabilizing at 6 dollars. Notably, there is an absence of Dispersion among the six analysts, as the high, low, and median targets coincide at the same value, indicating a complete technical consensus on the expected fair value of the stock at the current stage.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.